Top Markets
#1 GEKKO GEKKO +53.94%
#2 ADO Protocol ADO Protocol +38.79%
#3 Pons Pons +37.50%
#4 Prom Prom +32.61%
#5 Helium Helium +28.33%
#6 TENDIES TENDIES +25.51%
#7 Giggle Fund Giggle Fund +18.81%
#8 龙虾 (Lobster) 龙虾 (Lobster) +18.72%
#9 Main Street Yield Main Street Yield +17.48%
#10 o1.exchange o1.exchange +17.29%
Coin of the day
GEKKO GEKKO
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Kolon TissueGene, Inc. Kolon TissueGene, Inc.

Kolon TissueGene, Inc.

950160
Clasificación en acciones #9085
Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the... Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the advancement of clinical-stage cell-based treatments for osteoarthritis. Its flagship offering is TG-C, a proprietary platform technology that integrates allogeneic primary cells with genetically engineered counterparts. Established by Kwan H. Lee on June 9, 1999, the enterprise maintains its corporate headquarters in Rockville, Maryland.
Precio por acción
$12.94
Última sincronización: 2026-08-28
Capitalización bursátil
$1.10B
Cambio (1 día)
-0.16%
Cambio (1 año)
-51.50%
País
US
Comercio Kolon TissueGene, Inc. (950160)

Categoría

Healthcare
Ratio P/B de Kolon TissueGene, Inc. (950160)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Kolon TissueGene, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Kolon TissueGene, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH